The estimated Net Worth of Gregory T Lucier is at least $26.6 Million dollars as of 8 August 2024. Mr. Lucier owns over 8,212 units of Nuvasive Inc stock worth over $2,649,735 and over the last 16 years he sold NUVA stock worth over $23,169,771. In addition, he makes $830,057 as Chairman of the Board at Nuvasive Inc.
Sign up
Mr. Lucier NUVA stock SEC Form 4 insiders trading
Gregory has made over 52 trades of the Nuvasive Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 8,212 units of NUVA stock worth $199,962 on 8 August 2024.
The largest trade he's ever made was exercising 569,522 units of Nuvasive Inc stock on 26 February 2010 worth over $28,920,327. On average, Gregory trades about 20,255 units every 46 days since 2008. As of 8 August 2024 he still owns at least 66,660 units of Nuvasive Inc stock.
You can see the complete history of Mr. Lucier stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gregory Lucier biography
Gregory T. Lucier serves as Chairman of the Board of the Company. Mr. Lucier is currently Chief Executive Officer of Corza Health, Inc. Mr. Lucier previously served as Chief Executive Officer of NuVasive from May 2015 to November 2018. Mr. Lucier has served as a member of our Board of Directors since December 2013 and our Chairman of the Board since November 2018. Mr. Lucier has over 25 years of executive management experience and served as Chairman and Chief Executive Officer of Life Technologies Corporation, a global biotechnology company, from May 2003 until its acquisition by Thermo Fisher Scientific Inc. in February 2014. Prior to joining Life Technologies, Mr. Lucier served as Chief Executive Officer and President at GE Medical Systems Information Technologies, Vice President for Global Services at GE Medical Systems and served as a corporate officer of the General Electric Corporation. Mr. Lucier’s executive experience in the biotechnology industry provides strategic and practical knowledge to our Board related to strategy, finance, regulatory, clinical research and other operational areas in our industry.
What is the salary of Gregory Lucier?
As the Chairman of the Board of Nuvasive Inc, the total compensation of Gregory Lucier at Nuvasive Inc is $830,057. There are 4 executives at Nuvasive Inc getting paid more, with J. Christopher Barry having the highest compensation of $5,425,440.
How old is Gregory Lucier?
Gregory Lucier is 56, he's been the Chairman of the Board of Nuvasive Inc since 2018. There are 5 older and 14 younger executives at Nuvasive Inc. The oldest executive at Nuvasive Inc is Donald Rosenberg, 69, who is the Independent Director.
What's Gregory Lucier's mailing address?
Gregory's mailing address filed with the SEC is C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE, NC, 28277.
Insiders trading at Nuvasive Inc
Over the last 22 years, insiders at Nuvasive Inc have traded over $60,917,905 worth of Nuvasive Inc stock and bought 185,079 units worth $8,372,956 . The most active insiders traders include Jesse I Treu, James C Blair und Brian H Dovey. On average, Nuvasive Inc executives and independent directors trade stock every 11 days with the average trade being worth of $415,308. The most recent stock trade was executed by Marc W. Rosenbaum on 1 March 2023, trading 1,829 units of NUVA stock currently worth $72,703.
What does Nuvasive Inc do?
nuvasive® is a place where we create new and innovative products at a speed that drives our ability to deliver absolute responsiveness®, and gives us a competitive edge. at nuvasive, we empower our shareowners to influence results and significantly contribute to the success of the company. together we make nuvasive a leader in the spine industry with our unique focus on speed of innovation®. every member of the nuvasive family has the opportunity to improve the lives of patients through their work. these life-changing career paths show how hard work, a competitive spirit and your unwavering dedication to the patient can take you and your career to new places. in addition to being a great place to have a career, we’re also committed to giving back and supporting our communities. through an attitude of gratitude, nuvasive provides life-changing spinal surgery to disadvantaged communities through our nonprofit, the nuvasive spine foundation®, and offers patient-to-patient support through
What does Nuvasive Inc's logo look like?
Complete history of Mr. Lucier stock trades at Atyr Pharma Inc, DENTSPLY Sirona Inc, Nuvasive Inc, Catalent, Maravai Lifesciences und Berkeley Lights
Nuvasive Inc executives and stock owners
Nuvasive Inc executives and other stock owners filed with the SEC include:
-
J. Christopher Barry,
Chief Executive Officer, Director -
J. Christopher Barry,
CEO & Director -
Nathaniel Sisitsky,
Senior Vice President, General Counsel, Corporate Secretary -
Matthew K. Harbaugh,
Exec. VP & CFO -
Gregory Lucier,
Chairman of the Board -
Nathaniel B. Sisitsky Esq.,
Sr. VP, Gen. Counsel & Corp. Sec. -
Lucas Vitale,
Sr. VP & Chief HR Officer -
Donald Rosenberg,
Independent Director -
Daniel Wolterman,
Independent Director -
Vickie Capps,
Independent Director -
Leslie Norwalk,
Independent Director -
R. Scott Huennekens,
Independent Director -
Robert Friel,
Independent Director -
John DeFord,
Independent Director -
Suzanne Hatcher,
Vice President, Internal & External Affairs -
Dale Wolf,
Senior Vice President - Global Operations -
Massimo Calafiore,
Executive Vice President - Global Business Units -
Brent Boucher,
Executive Vice President - Global Commercial -
Lucas Vitale,
Chief Human Resource Officer -
Matthew Harbaugh,
Executive Vice President, Chief Financial Officer -
Marc Rosenbaum,
VP, Corp. Controller & Chief Accounting Officer -
Michael Farrington,
VP of Corp. Marketing, Brand & Communication -
Juliet C. Cunningham,
VP of Investor Relations -
Ryan Donahoe,
Chief Technology Officer -
Dale A. Wolf,
Sr. VP of Global Operations -
Lisa Pecora,
VP & Head of Global Commercial Fin. -
Frank Middeke,
Managing Director of DACH -
Sean Freeman,
Sr. VP of Strategy & Corp. Devel. -
Johnson Lai,
Chief Information Officer -
Jereme M Sylvain,
Chief Accounting Officer -
Jack R Blair,
Director -
Peter Michael Leddy,
Director -
Edmund J Roschak,
CEO, NuVasive Spec. Orthopedic -
Dan Wolterman,
Director -
Michael D Ohalleran,
Director -
Lesley H Howe,
Director -
Peter C Farrell,
Director -
Joan Stafslien,
EVP and General Counsel -
Quentin S. Blackford,
CFO and CAO -
Cox Carol,
EVP Strategy, Corp Dev -
Tyler Lipschultz,
EVP, Biologics -
Andrew C. Morton,
SVP, CHRO -
Matthew Link,
President -
Rajesh Asarpota,
CFO -
Paul Mc Clintock,
President, U.S. Commercial -
Stephen Rozow,
EVP, Global Process -
Jeffrey P Rydin,
Senior V.P., U.S. Sales -
Jason Hannon,
VP, Legal Affairs & Secretary -
Patrick Miles,
Senior VP, Marketing -
Kevin C Oboyle,
CFO and Executive VP -
James C Blair,
Director -
James J Skinner,
VP,Strategic Sales Development -
Jonathan Spangler,
VP & Chief Patent Counsel -
G Bryan Cornwall,
VP, Research & Development -
Hansen A Yuan,
Director -
Arda Minocherhomjee,
Director -
Blair Capital Management Vi...,
-
Perkins Caufield & Byers Vi...,
10% owner -
Joseph Lacob,
Director -
G Rogan Fry,
Sr. V. P., Corp. Development -
Viii Associates Lp Kpcb,
10% owner -
Life Sciences Zaibatsu Fund...,
10% owner -
Iv Associates Lp Dp,
10% owner -
Jesse I Treu,
10% owner -
Kathleen K Schoemaker,
10% owner -
Brian H Dovey,
10% owner -
Vii Associates Lp Kpcb,
10% owner -
De Depot Et Placement Du Qu...,
10% owner -
Management Partners Iv Lpen...,
-
Partners Iv Lp Domain,
10% owner -
Viii Founders Fund L P Kpcb,
10% owner -
Russell Powers,
Exec. VP Sales Int'l Ops -
Eileen M More,
Director -
Keith Valentine,
President -
Alexis V Lukianov,
CEO and Chairman -
Michael E Paolucci,
Exec. V.P., Global HR -
Craig E Hunsaker,
SVP, Global Human Resources -
Richard Iii Treharne,
Director -
Michael Lambert,
CFO and Executive VP -
Robert J Hunt,
Director -
Siddhartha Kadia,
Director -
Amy Belt Raimundo,
Director -
Michael Farrington,
SVP, People and Culture -
Marc W. Rosenbaum,
Chief Accounting Officer